Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: a review on behalf of the CC AFU.

Fiche publication

Date publication

mai 2024

Journal

The French journal of urology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Bentahila R, Bensalah K, Benziane-Ouaritini N, Barthelemy P, Rioux-Leclerc N, Correas JM, Belhomme S, Bigot P, Sargos P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38823486

Résumé

The incidence of localized renal cell carcinoma (RCC) is on the rise among individuals aged 70 and older. While the gold standard for treatment remains surgical resection, some elderly and frail patients with comorbidities are not eligible for this procedure. In selected cases, percutaneous thermal ablation, such as cryotherapy, microwave and radiofrequency, offers less invasive options. General anesthesia is sometimes necessary for such treatments, but most of the procedures can be conducted using mild or deep conscious sedation. This approach is preferably recommended for small cT1a tumors situated at a distance from the renal hilum and/or ureter. Active surveillance remains an alternative in the case of small low grade RCC although it may induce anxiety in certain patients. Recent research has highlighted the potentials of Stereotactic Ablative Body Radiotherapy (SABR) as a non-invasive, well-tolerated, and effective treatment for small renal tumors. This narrative review aims to explore recent advances in SABR for localized RCC, including appropriate patient selection, treatment modalities and administration, as well as efficacy and tolerance assessment.